Business Context and Reporting Period
This Form 6-K filing by OKYO Pharma Ltd covers the reporting period of January 5, 2026. The filing serves to disclose a significant change in executive leadership effective immediately.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of corporate governance changes and contains no financial performance data.
Material Changes
- Executive Leadership: Robert J. Dempsey has assumed the role of Chief Executive Officer.
- Role Transition: Gary S. Jacob, Ph.D., has transitioned to the role of Chief Development Officer.
- Board Composition: Gary S. Jacob, Ph.D., will continue to serve as a member of the Board of Directors.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, future outlook, management commentary on operations, or specific risk factors. The document notes that the attached news announcement (Exhibit 99.1) is furnished but not deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the official press release (Exhibit 99.1) for detailed biographies of Robert J. Dempsey and Gary S. Jacob, Ph.D.
- Confirm the effective date of the leadership transition is January 5, 2026.
- Review subsequent filings for any strategic shifts resulting from the new CEO appointment.